Agenus Inc.
AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulā¦ read more
Healthcare
Biotechnology
25 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.34
Price+0.23%
$0.01
1Y
Price
Market Cap
$147.135m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-52.8%
EBITDA Margin-108.8%
Net Profit Margin-78.7%
Free Cash Flow MarginRevenue
$101.706m
-1.7%
1y CAGR+8.0%
3y CAGR-10.7%
5y CAGREarnings
-$165.520m
+27.1%
1y CAGR+7.7%
3y CAGR-199.2%
5y CAGREPS
-$7.15
+32.5%
1y CAGR+22.5%
3y CAGR-143.4%
5y CAGRBook Value
-$336.308m
$185.221m
Assets$521.529m
Liabilities$402.757m
DebtDebt to Assets
217.5%
-5.2x
Debt to EBITDAFree Cash Flow
-$127.362m
+19.8%
1y CAGR+16.5%
3y CAGR-203.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company